Tonix Pharmaceuticals Holding Corp., a fully integrated, commercial-stage biotechnology company, has scheduled a conference call and webcast for Monday, Nov. 9, 2026, at 8:30 a.m. ET to report its third-quarter 2026 financial results and operational highlights. The announcement, issued via NetworkNewsWire, provides shareholders and prospective investors with a timely window into the company’s performance and strategic progress.
Investors and interested parties can register to participate in the conference call or view the webcast through the company. A replay will be available under “IR Events” in the Investors section of the Tonix website. The full press release is accessible at https://nnw.fm/va44Q.
Tonix is focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its recently approved flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace® SymTouch® and Tosymra®. Tonix is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
Beyond its commercial portfolio, Tonix’s CNS pipeline includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. The company is also advancing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and they have not been approved for any indication.
The upcoming financial report is significant because it will give investors a clearer picture of how Tonix is executing on its commercial launch of TONMYA and managing its broader pipeline. With the first new fibromyalgia treatment in over 15 years, Tonix addresses a large unmet need and could set a new standard of care. The company’s progress in CNS and immunology also positions it in high-growth therapeutic areas, potentially attracting partnership or investment interest.
For those tracking Tonix, the latest news and updates are available in the company’s newsroom at https://nnw.fm/TNXP. NetworkNewsWire, a specialized communications platform, is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. The platform’s reach includes editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. For full terms and disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer.
